High pathological complete remission rates with paclitaxel and carboplatin ± trastuzumab (TC±H) following dose dense doxorubicin and cyclophosphamide (AC) supported by GM-CSF in breast cancer-a phase I study.

被引：0
|
作者：
Mehta, RS [1 ]
Schubbert, T [1 ]
Hsiang, D [1 ]
Butler, J [1 ]
Baick, C [1 ]
Su, MY [1 ]
机构：
[1] Univ Calif Irvine, Orange, CA 92668 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 33 条
  • [21] Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer
    M I Koukourakis
    A Giatromanolaki
    S Kalokyris
    M Froudarakis
    V Georgoulias
    G Retalis
    N Bahlitzanakis
    Medical Oncology, 2000, 17 : 135 - 143
  • [22] Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity.
    Morris, P. G.
    Chen, C.
    Lin, N.
    Moy, B.
    Come, S.
    Abbruzzi, A.
    Patil, S.
    Winer, E.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    CANCER RESEARCH, 2009, 69 (24) : 675S - 675S
  • [23] Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib
    Morris, P. G.
    Chen, C.
    Lin, N.
    Moy, B.
    Come, S.
    Abbruzzi, A.
    Winer, E.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 271 - 271
  • [24] Abrogation of the hematological activities of the GM-CSF/IL-3 fusion protein (PIXY321) by anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin: Results of a phase I study.
    Miller, LL
    Korn, EL
    Stevens, DS
    Janik, JE
    Gause, BL
    Kopp, WC
    Longo, DL
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 2012 - 2012
  • [25] Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
    Schneeweiss, Andreas
    Moebus, Volker
    Tesch, Hans
    Hanusch, Claus
    Denkert, Carsten
    Luebbe, Kristina
    Huober, Jens
    Klare, Peter
    Kuemmel, Sherko
    Untch, Michael
    Kast, Karin
    Jackisch, Christian
    Thomalla, Joerg
    Ingold-Heppner, Barbara
    Blohmer, Jens-Uwe
    Rezai, Mahdi
    Frank, Matthias
    Engels, Knut
    Rhiem, Kerstin
    Fasching, Peter Andreas
    Nekljudova, Valentina
    von Minckwitz, Gunter
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 181 - 192
  • [26] Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    Sikov, William M.
    Berry, Donald A.
    Perou, Charles M.
    Singh, Baljit
    Cirrincione, Constance T.
    Tolaney, Sara M.
    Kuzma, Charles S.
    Pluard, Timothy J.
    Somlo, George
    Port, Elisa R.
    Golshan, Mehra
    Bellon, Jennifer R.
    Collyar, Deborah
    Hahn, Olwen M.
    Carey, Lisa A.
    Hudis, Clifford A.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (01) : 13 - U34
  • [27] Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
    Schneeweiss, Andreas
    Michel, Laura L.
    Moebus, Volker
    Tesch, Hans
    Klare, Peter
    Hahnen, Eric
    Denkert, Carsten
    Kast, Karin
    Pohl-Rescigno, Esther
    Hanusch, Claus
    Link, Theresa
    Untch, Michael
    Jackisch, Christian
    Blohmer, Jens-Uwe
    Fasching, Peter A.
    Solbach, Christine
    Schmutzler, Rita K.
    Huober, Jens
    Rhiem, Kerstin
    Nekljudova, Valentina
    Luebbe, Kristina
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 100 - 111
  • [28] Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells:: a phase I/II study in advanced ovarian cancer
    Wandt, H
    Birkmann, J
    Denzel, T
    Schäfer, K
    Schwab, G
    Pilz, D
    Egger, H
    Both, A
    Gallmeier, WM
    BONE MARROW TRANSPLANTATION, 1999, 23 (08) : 763 - 770
  • [29] Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer
    H Wandt
    J Birkmann
    Th Denzel
    K Schäfer
    G Schwab
    D Pilz
    H Egger
    A Both
    WM Gallmeier
    Bone Marrow Transplantation, 1999, 23 : 763 - 770
  • [30] A phase II study of dose-dense chemotherapy (doxorubicin (A), cyclophosphamide (C), paclitaxel (T), gemcitabine (G)) supported by pegfilgrastim (P) and darbepoetin-alfa (D) for patients with high-risk early stage breast cancer (ICANDO)
    Mainwaring, P. N.
    Shannon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
1234